Stories about the people, science and research of the Medical Research Council.
8 Mar 2016
In ‘To the Crick! Part 1: Moving home after 100 years’ we talked about how items like personal papers from the MRC National Institute for Medical Research (NIMR) archives are in need of a new home. The papers of one of NIMR’s most famous names, Rosa Beddington, are being rehoused in the archive of The Royal Society. Royal Society archivist Laura Outterside is celebrating the arrival of the first collection of personal papers from a female Fellow of the Royal Society (FRS). This post was originally published on The Respository and has been adapted and reproduced here with kind permission from The Royal Society.
Rosa Beddington on admissions day in 1999 when she became a Fellow of the Royal Society. ©The Royal Society
What better way for the Royal Society archive to celebrate International Women’s Day than by welcoming our first collection of personal papers from a female Fellow? We’ve recently had the good news that the Royal Society archive will be the new home for the papers of Rosa Beddington, a developmental biologist at the NIMR who became a Fellow of the Royal Society in 1999. [...]
Continue reading: To the Crick! Part two: The Royal Society welcomes its first collection of personal papers from a female Fellow
17 Aug 2015
They started out as a useful tool for studying the immune system in the lab and now they’re a family of drugs treating millions of patients, with global revenues of nearly $75 billion in 2013. MRC funding and researchers have been entwined with the monoclonal antibodies story from the very beginning. Forty years ago this month, Nature published a paper by César Milstein and Georges Köhler which described how they’d made mouse monoclonal antibodies. Here we look at the landmarks on the 40-year journey.
They can fight disease, determine blood types, and diagnose pregnancy in minutes. Such varied uses, but the usefulness of monoclonal antibodies actually lies in their uniformity.
Antibodies are proteins that recognise and fight foreign invaders, such as bacteria or viruses. Monoclonal antibodies are tailored in the lab to recognise specific desirable targets, such as a marker on a cancer cell or a pregnancy hormone. They are then churned out in their identical multitudes, ready to become a drug, a diagnostic test, or a probe to study disease in the lab. [...]
Continue reading: From tool to therapy: a timeline of monoclonal antibody technology